News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Cloudastructure set its Q1 2026 earnings call for July 17.
  • Cloudastructure delayed its Q1 filing over convertible preferred stock accounting and amended Series 2 terms.
  • The company said the accounting change is non-cash and does not affect cash flow or operations.
  • BHP reported a quarter-on-quarter rebound in iron ore production and a record annual iron ore tally.
  • BHP maintained fiscal targets while copper output rose sequentially but fell year-on-year.
  • BHP warned a Port Hedland worker strike and South Australia operational snags could disrupt near-term shipments.

Latest Articles

BrewDog Rolls Back Pint Prices to £2 Across Scotland for 72-Hour Bank Holiday Weekend, Celebrating the National Team’s Return

BrewDog Rolls Back Pint Prices to £2 Across Scotland for 72-Hour Bank Holiday Weekend, Celebrating the National Team’s Return

Tilray Brands' BrewDog is marking Scotland's national football team return with a limited-time promotion that rolls pint prices back to £2 at Scottish BrewDog bars for a 72-hour weekend and launches a £19.98 online beer bundle. This campaign aims to increase footfall, celebrate local heritage, and expand e-commerce sales, supporting BrewDog's broad…

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

Tonix Pharmaceuticals Holding Corp., a US-listed biotechnology company specializing in CNS and immunology treatments, announced its executive team's participation in BTIG Infectious Disease Day 2026, held virtually on June 16, 2026. The company focuses on commercial-stage products for fibromyalgia and migraines, while advancing a pipeline addressin…

Aqua Metals Selected as Industrial Partner on DOE-Funded Idaho National Laboratory Program Advancing Critical Minerals Refining

Aqua Metals Selected as Industrial Partner on DOE-Funded Idaho National Laboratory Program Advancing Critical Minerals Refining

Aqua Metals, Inc. has been selected as the industrial partner in a DOE-funded program led by Idaho National Laboratory to develop electrochemical methods for refining nickel and cobalt from lithium-ion battery recycling streams. This collaboration leverages Aqua Metals' pilot facilities and expertise to enhance domestic critical minerals refining t…

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Climb Bio announced initial Phase 1b clinical data demonstrating that Budoprutug, an anti-CD19 monoclonal antibody, exhibits an encouraging safety profile, robust B-cell depletion, and meaningful platelet response in heavily pretreated adult patients with primary immune thrombocytopenia (ITP). The data were presented at the European Hematology Asso…

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Purple Biotech Ltd. presented new preclinical data at EACR 2026 showcasing its lead immunotherapy candidate IM1240, part of the CAPTN-3 platform. The data indicate significant improvements in pharmacokinetics, safety, and anti-tumor efficacy, particularly in immunotherapy-resistant cancers such as head and neck, bladder, and non-small cell lung can…

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Nurix Therapeutics announced updated Phase 1a/b clinical trial results for bexobrutideg (NX-5948), an oral BTK degrader, demonstrating high objective response rates and durable progression-free survival in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients, including those with prior BTK inhibitor resista…

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Syndax Pharmaceuticals announced the publication and presentation of Phase 1/2 SAVE trial data evaluating an all-oral combination of Revuforj (revumenib), decitabine/cedazuridine, and venetoclax in patients with relapsed or refractory acute myeloid leukemia (AML) characterized by NPM1 mutation, KMT2A rearrangement, or NUP98 rearrangement. The trial…

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

AC Immune SA, a clinical-stage biopharmaceutical company listed on NASDAQ (ticker: ACIU), announced it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation. The grant will fund an extension of Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, an active immunotherapy targeting alpha-synuclein in early…

Pharvaris Announces Annual General Meeting of Shareholders

Pharvaris Announces Annual General Meeting of Shareholders

Pharvaris announced its Annual General Meeting of shareholders scheduled for June 26, 2026. The company is advancing its late-stage biopharmaceutical pipeline focused on oral bradykinin B2 receptor antagonists targeting hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Pharvaris is preparing marketing a…

Kimco Realty OP, LLC Announces Pricing of Upsized $525.0 Million Exchangeable Senior Notes Offering

Kimco Realty OP, LLC Announces Pricing of Upsized $525.0 Million Exchangeable Senior Notes Offering

Kimco Realty OP, LLC priced $525 million of 3.50% exchangeable senior notes due 2031, increased from $500 million, with proceeds to partially repurchase common stock and for general corporate purposes including debt repayment and acquisitions. Notes are exchangeable into Kimco common stock at a premium and carry optional redemption features. The of…

Kremlin Says EU’s Proposed Bank Sanctions Will Not Dent Russian Lenders

Kremlin Says EU’s Proposed Bank Sanctions Will Not Dent Russian Lenders

The Kremlin said proposed European Union sanctions directed at Russian banks and cryptocurrency networks will not harm banks' operations or profits, arguing that the country’s largest lenders have functioned under long-standing restrictions without adverse effects. Kremlin spokesman Dmitry Peskov cited ongoing central bank oversight and President P…

Goldman Economists See ECB Raising Rates by 25 Basis Points

Goldman Economists See ECB Raising Rates by 25 Basis Points

Goldman Sachs economists expect the European Central Bank to lift its policy rate by 25 basis points at its forthcoming meeting on Thursday. The bank anticipates upward revisions to core inflation forecasts for 2027 and 2028 driven by a more persistent shock, consistent with their view that energy disruptions will have lasting effects. Markets have…

Serbia and MOL Resolve Terms Over NIS Stake; State to Gain Contingent 5% Holding

Serbia and MOL Resolve Terms Over NIS Stake; State to Gain Contingent 5% Holding

Serbia said it has cleared outstanding issues with Hungary's MOL Group concerning a potential transaction involving Naftna Industrija Srbije (NIS). Under the arrangement, Belgrade would acquire an additional 5% of NIS if MOL and Gazprom Neft complete a deal for the 56.15% stake currently held by the Russian parties, a move that would strengthen Ser…

Markets Grapple with Renewed Inflation Fears and Central Bank Moves

Markets Grapple with Renewed Inflation Fears and Central Bank Moves

Markets face a confluence of pressures - rising inflation, geopolitical tension in the Gulf, earnings setbacks at major tech names and imminent central bank rate decisions. Headline inflation has climbed back to 4.2%, while May core CPI was marginally cooler than forecast. Investors are awaiting U.S. producer price data and several high-profile mon…

Agencia Comercial Spirits Ltd Announces Power Supply Agreements with PLN for Indonesia AI Data Center Project

Agencia Comercial Spirits Ltd Announces Power Supply Agreements with PLN for Indonesia AI Data Center Project

Agencia Comercial Spirits Ltd, a Taiwan-based whisky importer and distributor listed on NASDAQ, announced that its Indonesian subsidiary has entered into additional electricity supply agreements with Indonesian state-owned PLN to support its planned AI computing infrastructure project in Indonesia. The agreements establish a dual-feed power supply …